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p53 is a frequent target for mutation in human
tumors, and mutant p53 proteins can actively
contribute to tumorigenesis. We employed a three-
dimensional culture model in which nonmalignant
breast epithelial cells form spheroids reminiscent
of acinar structures found in vivo, whereas breast
cancer cells display highly disorganized mor-
phology. We found that mutant p53 depletion is suffi-
cient to phenotypically revert breast cancer cells to a
more acinar-like morphology. Genome-wide expres-
sion analysis identified the mevalonate pathway as
significantly upregulated by mutant p53. Statins
and sterol biosynthesis intermediates reveal that
this pathway is both necessary and sufficient for
the phenotypic effects ofmutant p53 on breast tissue
architecture. Mutant p53 associates with sterol gene
promoters at least partly via SREBP transcription
factors. Finally, p53 mutation correlates with highly
expressed sterol biosynthesis genes in human
breast tumors. These findings implicate the mevalo-
nate pathway as a therapeutic target for tumors
bearing mutations in p53.
INTRODUCTION
The TP53 gene is themost frequent target formutation in tumors,
with more than half of all human cancers exhibiting mutation at
this locus (Vogelstein et al., 2000). Unlikemost tumor suppressor244 Cell 148, 244–258, January 20, 2012 ª2012 Elsevier Inc.genes, which are predominantly inactivated as a result of dele-
tion or truncation, themajority of mutations in TP53 aremissense
mutations, a few of which cluster at ‘‘hot spot’’ residues in the
DNA-binding core domain (Petitjean et al., 2007). In contrast to
wild-type p53, which under unstressed conditions is a very
short-lived protein, these missense mutations lead to the accu-
mulation of full-length p53 protein with a prolonged half-life
(Brosh and Rotter, 2009). Mutant forms of p53 can exert onco-
genic, or gain-of-function, activities independent of their effects
on wild-type p53. In vivo knockin mice harboring two tumor-
derived mutants of p53 (equivalent to R175H and R273H in
humans) display an altered tumor spectrum as well as more
metastatic tumors when compared to p53 null mice (Lang
et al., 2004; Olive et al., 2004). The mutational status of p53
has been shown to predict poor outcomes in multiple types of
human tumors, including breast cancer (Olivier et al., 2006;
Petitjean et al., 2007). Mutant p53 expression correlates with
increased survival, invasion, migration, and metastasis in
preclinical breast cancer models (Adorno et al., 2009; Muller
et al., 2009; Stambolsky et al., 2010).
Breast cancer is thought to arise from mammary epithelial
cells found in structures referred to as acini, which collectively
form terminal ductal lobular units. Each acinus consists of
a single layer of polarized luminal epithelial cells surrounding
a hollow lumen (Bissell et al., 2002). Though traditional two-
dimensional (2D) cell culture has provided insight into the
process of breast carcinogenesis, such in vitro culture condi-
tions differ from the microenvironment that a cell would experi-
ence in vivo (Bissell et al., 2002). By contrast, a laminin-rich
extracellular matrix allows normal mammary epithelial cells to
form three-dimensional (3D) structures reminiscent of acinar
structures found in vivo (Petersen et al., 1992). Because one of
the hallmarks of breast tumorigenesis is the disruption of
mammary tissue architecture, 3D culture conditions allow one
to readily distinguish normal and tumorigenic tissue by morpho-
logical phenotype (Petersen et al., 1992). In addition, inhibition of
key oncogenic signaling pathways is sufficient to phenotypically
revert breast cancer cells grown in 3D culture (Bissell et al.,
2005). Here, we show that the mevalonate pathway is both
necessary and sufficient for the disruption of acinar morphology
by mutant p53 and reveal a potential mechanism by which
mutant p53 increases expression of the genes in the mevalonate
pathway.
RESULTS
Mutant p53 Depletion in Breast Cancer Cells Leads
to a Phenotypic Reversion in 3D Culture
To investigate the role of mutant p53 in breast cancer, we em-
ployed a 3D culture protocol in which mammary epithelial cells
are grown in a laminin-rich extracellular matrix. We examined
the 3D morphologies of two cell lines derived from metastatic
breast tumors that each expresses exclusively a single mutant
p53 allele: MDA-231 (R280K) andMDA-468 (R273H). These cells
were engineered to expressmiR30-based doxycycline-inducible
shRNA targeting endogenous mutant p53 in the 30UTR (desig-
nated MDA-231.shp53 and MDA-468.shp53). In both cases,
mutant p53 reduction by shRNA led to dramatic changes in the
behavior of the cells when cultured in a 3D microenvironment.
MDA-231 cells, when grown in 3D culture, normally exhibit an
extremely disordered and invasive morphology, which has
been characterized as ‘‘stellate’’ (Kenny et al., 2007). Depleting
these cells of mutant p53 in 3D culture conditions almost
completely abrogated the stellate morphology of large, invasive
structures with bridging projections (Figure 1A). Instead, MDA-
231 cells with reduced p53 developed smaller, less invasive
appearing cell clusters. By titrating doxycycline, we observed a
progressive loss of malignant, invasive characteristics as a func-
tion of decreasing levels of mutant p53 (Figures S1A and S1B
available online). Although this reduction in invasive behavior in
3D culture supports the recent findings that mutant p53
promotes the invasion of breast cancer cells (Adorno et al.,
2009; Muller et al., 2009), MDA-231 cells with reduced p53 did
not assume the ordered acinus-like morphology that is charac-
teristic of nonmalignant mammary epithelial cells.
MDA-468 cells exhibit a less invasive but highly disorganized
appearance and have been classified as ‘‘grape-like’’ (Kenny
et al., 2007). Under 3D culture conditions, MDA-468.shp53 cells
displayed three types of cellular morphologies: (1) constellations
of cells with a highly disordered ‘‘malignant’’ appearance that
comprise about 30%–40% of the population, (2) spherical cell
clusters with an ‘‘intermediate’’ morphology that, though disor-
dered, appear less malignant (about 55%–65% of the popula-
tion), and (3) a very small proportion (<5%) of structures that
closely resemble small acini and contain a hollow lumen (exam-
ples of these categories are shown in Figure 1C). Strikingly,
when mutant p53 was depleted from these cells, a significant
proportion of the population underwent a full phenotypic rever-
sion from highly disorganized structures to acinus-like structures
with a hollow lumen (Figure 1D). These reverted structures alsodisplay proper localization of a6 integrin, suggesting that they
have regained apicobasal polarization (Figure S1E). Using either
a stable pool of MDA-468.shp53 cells (Figure 1F) or a stable
clone derived from these cells (Figure 1G), we observed a signif-
icant increase in the hollow lumen population upon mutant
p53 depletion, with nearly 50% of the population falling into
this acinus-like morphology in the latter case. Whereas in the
experiment shown in Figure 1G, we observed a decrease in
predominantly the intermediate population upon reversion to
hollow lumen structures, in other cases, we observed a decrease
in both malignant and intermediate populations (e.g., Figure 4A,
below). Because the stable clone of MDA-468.shp53 cells
exhibited a higher degree of reversion, all further experiments
were carried out using these cells. Importantly, as both breast
cancer cell lines express only mutant p53, these phenotypic
changes may be attributed directly to the reduction in mutant
p53 levels.
MDA-468.shp53 cells were then engineered to express an
shRNA-resistant version of p53-R273H or a control vector
(Figures 2A and 2B). Introducing this version of mutant p53 into
MDA-468.shp53 cells prevented the phenotypic reversion that
normally occurs after depleting cells of mutant p53 (Figure 2B),
and the exogenous and endogenous p53 proteins together led
to an even more highly disorganized and invasive phenotype
than parental cells (compare left panels of Figures 2A and 2B).
Wild-type p53 primarily functions as a transcription factor, and
the transactivation domains of p53 have previously been impli-
cated in oncogenic functions of mutant p53 (Lin et al., 1995;
Matas et al., 2001; Yan and Chen, 2010). To interrogate the
role of the transactivation domains in the effects of mutant p53
in 3D culture, we engineered MDA-468.shp53 cells to express
an shRNA-resistant version of the endogenous mutant p53 that
had been mutated at four key residues (L22Q/W23S/W53Q/
F54S) shown previously to render its transactivation domains
nonfunctional (Lin et al., 1994; Venot et al., 1999). As opposed
tomutant p53with a functional transactivation region (Figure 2B),
the transactivation-dead version of mutant p53 failed to rescue
the phenotypic reversion (Figure 2C), suggesting that the onco-
genic effects in this system were due to transcriptional changes
mediated by mutant p53.
To test whether the effects ofmutant p53 on 3Dmorphology of
breast cancer cells were generalizable between tumor-derived
mutants of p53, we replaced the endogenous mutant p53 in
MDA-231 cells (R280K) with an shRNA-resistant version of
p53-R273H, the mutant that is endogenously expressed in
MDA-468 cells. Though control cells behaved like the cells with
just the shRNA-targeting p53, expression of p53-R273H partially
prevented the phenotypic changes of depleting endogenous
p53-R280K (Figure S1F).
Nonmalignant MCF10A mammary cells with wild-type p53
undergo a well-characterized progression of three-dimensional
morphogenesis, which results in spherical acinus-like structures
(Debnath et al., 2003; Petersen et al., 1992) (Figure S2A). We
engineered the nonmalignant human mammary epithelial
cell line, MCF10A, to express Flag-tagged versions of the five
most frequent p53 mutants found in breast tumors (p53-
R175H, -R248Q, -R273H, -R248W, and -G245S) (http://p53.
free.fr). MCF10A cells infected with a control vector exhibitedCell 148, 244–258, January 20, 2012 ª2012 Elsevier Inc. 245
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Figure 1. Depletion of Mutant p53 from Breast Cancer Cells Induces a Phenotypic Reversion in 3D Culture
(A) MDA-231.shp53 cells were grown under 3D conditions for 8 days in the absence or presence of DOX to induce an shRNA targeting p53. Representative
differential interference contrast (DIC) images are shown. Scale bar, 200 mm.
(B) MDA-231.shp53 cells grown as in (A) prior to immunoblotting analysis. p53 was detected using anti-p53 antibody (PAb1801).
(C) MDA-468.shp53 cells were grown in 3D cultures for 8 days, and confocal microscopic structures were grouped into the three indicated categories. Actin
(green) and nuclear (red) staining. Scale bar, 50 mm.
(D) MDA-468.shp53 cells were grown in 3D cultures for 8 days in the presence of DOX to deplete mutant p53. (Left) GFP (green) serves as a marker for shRNA
induction. (Right) Nuclei (red). The larger structure is representative of intermediate colonymorphologies, and the smaller structure is representative of acinus-like
structures with hollow lumen morphology. White arrow indicates apoptotic cell debris within the luminal space. Scale bar, 50 mm.
(E) MDA-468.shp53 cells were grown and processed as in (B).
(F) Morphometry: A stable pool of MDA-468.shp53 cells was grown in 3D cultures for 8 days in the presence or absence of DOX, and structures were analyzed
by confocal microscopy and categorized as in (C). (Left) Population distribution; (right) percent structures with hollow lumens. Data presented as mean ± SD.
*p < 0.01.
(G) Morphometry: A stable clone of MDA-468.shp53 cells was grown in 3D culture conditions and analyzed as in (F). An average of two experiments is shown.
See also Figure S1.
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Figure 2. Mutant p53 Requires Functional Trans-
activation Subdomains to Disrupt Morphology of
Mammary Cells in 3D Culture
(A) MDA-468.shp53 cells expressing a control vector were
grown in 3D cultures for 5 days in the absence (left) or
presence (right) of DOX. Representative DIC images are
shown. Scale bar, 200 mm.
(B) MDA-468.shp53 cells expressing an shRNA-resistant
Flag-tagged p53-R273H were grown in 3D cultures as in
(A). Scale bar, 200 mm.
(C) MDA-468.shp53 cells expressing an shRNA-
resistant Flag-tagged p53-R273H-mTAD (mutant p53 with
nonfunctional transactivation region, p53-R273H-L22Q/
W23S/W53Q/F54S) were grown in 3D cultures as in (A).
Scale bar, 200 mm.
(D) Cell lines in (A)–(C) were grown in 3D cultures as in (A)
and processed for immunoblotting for p53 (PAb240) or for
actin. Flag-tagged mutant p53 variants migrate more
slowly than endogenously expressed mutant p53.
See also Figure S2.normal acinar morphogenesis. However, as recently reported
(Zhang et al., 2011), expression of the four most frequent mutant
p53 proteins led to an inhibition of luminal clearance, reminiscent
of the filled lumen phenotype observed in ductal carcinoma
in situ (DCIS), with R273H and R248W exhibiting the highest
degree of luminal filling (Figures S2B–S2F). Further, transactiva-
tion-deficient versions (mTAD) of these same five p53 mutants
were unable to block luminal clearance in MCF10A cells, with
R273H and R248W displaying the highest dependence on their
transactivation domains (Figures S2I and S2J). Thus, not only
can depletion of mutant p53 from breast cancer cells lead to
a phenotypic reversion in 3D culture, but also mutant p53
expression in nonmalignant mammary epithelial cells is sufficient
to disrupt their morphology in 3D culture. The transactivation
domain of mutant p53 is required in both cases.
Tumor-DerivedMutants of p53Regulate theMevalonate
Pathway in Breast Cancer Cells
Based on the above findings, we performed genome-wide
expression profiling on MDA-468.shp53 cells grown in 3D
culture, with or without full levels of mutant p53. We identified
989 genes as significantly altered (p < 0.01) following shRNA-Cell 148, 24mediated downregulation of endogenous
mutant p53, suggesting that mutant p53 acts
promiscuously to affect many cellular pro-
cesses. To guide our identification of those
pathways/processes necessary for mutant p53
function in 3D culture, we employed two anal-
ysis methods: ingenuity pathway analysis (IPA)
and gene ontology (GO) analysis. The mevalo-
nate pathway was the most overrepresented
pathway using IPA (labeled ‘‘Biosynthesis of
Steroids’’ by Ingenuity); in fact, it was the only
pathway detected with 99% confidence (p <
0.01) following mutant p53 downregulation
(Figure 3A). This pathway, along with the related
isoprenoid biosynthetic process, was also de-tected using GO analysis as significantly downregulated upon
mutant p53 ablation across three independent experiments
(Figure 3B).
The mevalonate pathway is responsible for de novo choles-
terol synthesis as well as for many important nonsterol isopre-
noid derivatives (Figure S3) (Goldstein and Brown, 1990). Of
the many steps that convert acetyl-CoA to cholesterol, seven
genes (HMGCR, MVK, MVD, FDPS, SQLE, LSS, and DHCR7)
encoding enzymes within the mevalonate pathway were found
to be significantly reduced by mutant p53 depletion according
to IPA. We confirmed in separate experiments that expression
of all of these genes was markedly reduced (p < 0.005) when
mutant p53 was depleted by shRNA (Figure 3C). Using primers
for intron-containing transcripts, we also showed that p53-medi-
ated regulation of a subset of these genes in MDA-468 cells
occurs as a result of RNA transcription (as opposed to mRNA
stability or some later point of regulation) (data not shown).
The Effects ofMutant p53 onBreast CancerMorphology
Are Mediated through the Mevalonate Pathway
Elevated or deregulated activity of the mevalonate pathway has
been demonstrated in a number of different tumors, including4–258, January 20, 2012 ª2012 Elsevier Inc. 247
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Figure 3. Knockdown of Mutant p53 from Breast Cancer Cells in 3D Culture Significantly Downregulates the Mevalonate Pathway
(A) Data were analyzed through the use of ingenuity pathways analysis (Ingenuity Systems, http://www.ingenuity.com). Blue bars that cross the threshold line
(p < 0.05) represent pathways that are significantly changed following mutant p53 depletion from MDA-468 cells.
(B) Gene ontology (GO) analysis. 1, 2, and 3 represent three independent experiments. GO terms were sorted based on their significance, and redundant terms
were discarded.
(C) MDA-468.shp53 cells were grown in 3D cultures for 8 days in the presence or absence of DOX as indicated. qRT-PCR for the seven sterol biosynthesis genes
identified by IPA. Data represent mean ± SD of three independent experiments. **p < 0.005 by two-sided t test.
See also Figure S3.breast cancer, and a number of studies have suggested that
malignant cells are more highly dependent on the continuous
availability of mevalonate pathway metabolites than their non-
malignant counterparts (Buchwald, 1992; Larsson, 1996; Wong
et al., 2002). Though this pathway has been explored most
extensively in the context of cholesterol production, which is248 Cell 148, 244–258, January 20, 2012 ª2012 Elsevier Inc.necessary for membrane integrity and thus cell division, many
of the intermediate metabolites and side products play key roles
in other essential cellular processes. For example, farnesyl pyro-
phosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) are
critical for posttranslational modifications of Ras and RhoA,
respectively (Mo and Elson, 2004).
To test whether this pathway is necessary for the phenotypic
effects of mutant p53, add-back experiments were performed
in which breast cancer cells grown in 3D culture were depleted
of mutant p53 and supplemented with intermediate metabolites
produced by the mevalonate pathway. Addition of two upstream
metabolites, mevalonic acid (MVA) and mevalonic acid phos-
phate (MVAP), dramatically inhibited the phenotypic reversion
caused by mutant p53 knockdown in MDA-468 cells without
affecting the amount of p53 depletion (Figures 4A, S4A, and
S4B). This confirms that activity of the mevalonate pathway is
sufficient to compensate for the loss of mutant p53 and suggests
that upregulation of at least the initial steps of the mevalonate
pathway is necessary for the effects of mutant p53 on tissue
architecture.
HMG-CoA reductase, which catalyzes the formation of meva-
lonic acid, is the rate-limiting step in cholesterol biosynthesis
and the target of numerous cholesterol-reducing statins
(Larsson, 1996). The use of statins is well established in the
clinic to treat hypercholesterolemia, and there have been
multiple reports demonstrating that statins can exhibit anti-
cancer activity; however, their antitumorigenic mechanism has
not been firmly established.
We hypothesized that pharmacologic inhibition of the rate-
limiting enzyme in the mevalonate pathway might be sufficient
to mimic the effects of knocking down mutant p53. Strikingly,
we found that treatment of breast cancer cells in 3D culture
with Simvastatin, a lipophilic statin, used at clinically achievable
concentrations (Wong et al., 2002) resulted in a reduction in
growth in both cell lines, as well as extensive cell death in
MDA-468 cells (Figure 4B) and a significant reduction of the inva-
sive morphology of MDA-231 cells (Figure 4C). In fact, in MDA-
231 cells, the morphological changes seen with either statin
treatment or mutant p53 depletion were virtually the same. The
consequence of inhibiting the mevalonate pathway in MDA-468
cells was even more dramatic than mutant p53 downregulation
alone (cell death as opposed to formation of structures with a
hollow lumen). On the other hand, inhibition of HMG-CoA reduc-
tase in wild-type p53-expressing MCF10A cells did not result in
gross morphologic changes when used at clinically achievable
concentrations (Figure S4C). This suggests that breast cancer
cells bearing mutations in p53 upregulate the mevalonate
pathway and eventually become dependent upon its activity for
survival. Similar results were obtained with another lipophilic sta-
tin, Mevastatin (Figures S4D and S4E). Importantly, supplemen-
tation of MVA, the enzymatic product of HMG-CoA reductase,
to eitherMDA-468 orMDA-231 cells treatedwith a statin blocked
many of the phenotypic effects of statins (compare Figure 4D to
4B or 4C). These results indicate that the effects of statins on
breast cancer cells in 3D culture occur because of the function
of HMG-CoA reductase to produce mevalonic acid and further
implicate the upregulated mevalonate pathway in the malignant
3D phenotype of these cells. In addition, we tested whether flux
through themevalonate pathwaywas sufficient to disrupt normal
acinar morphogenesis. Similar to overexpression of tumor-
derived p53 mutants, exogenous MVA was sufficient to block
luminal clearance in MCF10A cells (Figure S4F).
We extended the effects of statins on breast cancer cells in
three other assays. First, we observed that Simvastatin cansignificantly impair anchorage-independent growth in both
MDA-468 and MDA-231 cells (Figure S5A). Second, in line with
findings that HMG-CoA reductase inhibitors induce cell-cycle
arrest and/or apoptosis in 2D culture (Graaf et al., 2004), we
noted a G1 cell-cycle arrest, with a concomitant drop in
S phase, in both breast cancer cell lines treated with 24 hr of
Simvastatin at varying concentrations (Figures S5B and S5C).
The phenotypic effects of statins in 3D culture are therefore
likely due to a combination of factors (i.e., decreased growth,
increased death, and decreased invasion). Third, consistent
with previous reports (Ghosh-Choudhury et al., 2010; Mori
et al., 2009) using a xenograft model of MDA-231 breast
cancer cells, Simvastatin significantly impaired tumor growth
of these cells when implanted into immunocompromised mice
(Figure S5D).
Geranylgeranylation Is Required for the Phenotypic
Effects of Mutant p53 in MDA-231 Breast Cancer Cells
Grown in 3D Culture
Next, we tested whether inhibition of later enzymes within the
mevalonate pathway would have similar phenotypic effects as
mutant p53 depletion from breast cancer cells grown in 3D
culture. An inhibitor of mevalonate decarboxylase, 6-Fluorome-
valonate, had remarkably similar phenotypic effects on both
MDA-468 and MDA-231 cells grown in 3D culture to that seen
with statin treatment (Figures 4E and 4F). Thus, not only HMG-
CoA reductase, but also several downstream enzymatic steps
in the mevalonate pathway are involved in the ability of mutant
p53 to maintain malignant behavior of breast cancer cells in 3D
culture conditions.
The mevalonate pathway is vital not only for producing cellular
cholesterol, but also as a source ofmany other biologically active
metabolites. We therefore examined whether the phenotypic
effects of mutant p53 knockdown were due to decreased
cholesterol synthesis or the production of an earlier metabolite.
To do this, we utilized three inhibitors that inhibit distinct actions
of the mevalonate pathway (Figure S3). YM-53601 inhibits
squalene synthase (and thus cholesterol production) at submi-
cromolar concentrations (Ugawa et al., 2000) but spares all
upstream intermediate metabolites. FTI-277 blocks farnesyla-
tion of proteins via inhibition of farnesyl transferase at nanomolar
concentrations in whole cells but has no effect on geranylgeranyl
transferase or squalene synthesis at low micromolar concentra-
tions (Lerner et al., 1995). GGTI-2133 blocks geranylgeranylation
of target proteins via inhibition of geranylgeranyl transferase
while sparing farnesylation and squalene synthesis (Vasudevan
et al., 1999).
At low micromolar concentrations, inhibition of squalene
synthase and farnesyl transferase had only a mild effect on the
growth of MDA-231 cells in 3D culture, whereas inhibition of
geranylgeranylation had a profound impact on both the growth
and the invasive morphology of these cells in 3D culture (Fig-
ure 5A). To examine whether downregulation of geranylgeranyla-
tion is necessary for the phenotypic effects observed after
mutant p53 depletion or HMG-CoA reductase inhibition, we per-
formed add-back experiments using geranylgeranyl pyrophos-
phate (GGPP) to cells either depleted of mutant p53 or treated
with Simvastatin (Figures 5B and 5C, respectively). BecauseCell 148, 244–258, January 20, 2012 ª2012 Elsevier Inc. 249
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Figure 4. The Mevalonate Pathway Is Both Necessary and Sufficient to Maintain the Malignant State of Breast Cancer Cells in 3D Culture
(A) MDA-468.shp53 cells were grown in 3D cultures for 8 days in the presence or absence of DOX to depletemutant p53. Parallel cultures grown in the presence of
DOX were supplemented with mevalonate pathway metabolites: mevalonic acid/mevalonic acid-phosphate (MVA/MVAP) beginning on day 1. Morphological
categories as indicated were determined using confocal microscopy and plotted as a percentage of the population. A representative experiment is shown here,
and a second representative experiment is shown in Figure S4.
(B) MDA-468 cells grown in 3D cultures for 13 days untreated or treated with DMSO, Simvastatin (100 nM), or Simvastatin (1 mM) as indicated. Representative DIC
images are shown. Drugs were added on day 4. Scale bar, 200 mm.
(C) MDA-231 cells grown in 3D cultures and treated as in (B). Scale bar, 200 mm.
(D) MDA-468 cells (top) or MDA-231 cells (bottom) were grown in 3D cultures for 13 days with Simvastatin (1 mM) as in (B) and (C), respectively, but were
supplemented with MVA/MVAP. Scale bar, 200 mm.
(E) MDA-468 cells were grown in 3D cultures for 8 days with DMSO or 6-Fluoromevalonate (200 mM), added on day 1 of the experiment. Scale bar, 200 mm.
(F) MDA-231 cells were grown as in (E). Scale bar, 200 mm.
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Figure 5. Modulation of Geranylgeranylation Mediates Many of the Phenotypic Effects of Mutant p53 Depletion and HMG-CoA Reductase
Inhibition in MDA-231 Cells
(A) MDA-231 cells were grown in 3D cultures for 8 days untreated or treated with DMSO or inhibitors YM-53601 (1 mM), FTI-277 (1 mM), or GGTI-2133 (1 mM), as
indicated. Drugs were added on day 1. Scale bar, 200 mm.
(B) MDA-231.shp53 cells were grown in 3D culture conditions for 9 days in the absence or presence of DOX as indicated. Parallel wells of cells that were grown
in the presence of DOX were supplemented with geranylgeranyl pyrophosphate (GGPP) (25 mM) beginning on day 1. Scale bar, 200 mm.
(C) MDA-231 cells were grown in 3D cultures for 13 days either treated with DMSO or Simvastatin (1 mM) as indicated. Parallel wells of cells that were grown in
the presence of Simvastatin (1 mM) were supplemented with GGPP (25 mM) beginning on day 1. Scale bar, 200 mm.
See also Figure S5.supplementation with GGPP was sufficient to rescue the inva-
sive phenotype in a portion of the population of MDA-231 cells
in 3D culture, this suggests that geranylgeranylation is indeed
a vital component of why mutant p53 upregulates the mevalo-
nate pathway in cancer cells.Mutant p53 Is Recruited to the Promoters of Genes
Encoding Mevalonate Pathway Enzymes
Much of the physiologic regulation of the sterol biosynthesis
enzymes takes place at the transcriptional level in a manner
that requires the sterol regulatory element-binding proteins,Cell 148, 244–258, January 20, 2012 ª2012 Elsevier Inc. 251
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Figure 6. Mutant p53 Is Recruited to Mevalonate Pathway Gene Promoters, and This Recruitment Is Dependent on SREBP Proteins
(A) 293 cells were transfected with Flag-p53-R273H and either Myc-mSREBP-1a, -1c, or -2. Cells were subjected to crosslinking with formaldehyde prior to lysis,
sonication, and immunoprecipitation, as described in Experimental Procedures followed, by SDS-PAGE and immunoblotting with anti-Myc (top) and anti-Flag
(bottom). Input is 2.5% of IP sample.
(B) Nuclear lysates from serum-starved MDA-468.shp53 cells were immunoprecipitated with an anti-SREBP-2 antibody (1D2) or Mouse IgG (Mock IP) and then
immunoblotted with anti-SREBP-2 (1D2) and anti-p53 antibodies (DO-1). Input is 10% of IP sample.
(C) MDA-468.shp53 cells were grown in 2D cultures for 8 days in the absence or presence of DOX and subjected to ChIP analysis as described in Experimental
Procedures. Mock IP (C) serves as a negative control. Data are presented asmean ±SD of three independent experiments. Values were normalized to the highest
immunoprecipitation signal. **p < 0.01; * p < 0.05 compared to all of the following: negative site, +DOX, and Mock IP.
(D) MDA-468.shp53 cells were grown and analyzed as in (C) to examine mutant p53 association with the HMGCR promoter. ** p < 0.01 compared to all of the
following: negative site, +DOX, Mock IP, and upstream and downstream sites. Genomic locations of PCR primers are illustrated in the HMGCR promoter. SRE-1
denotes sterol regulatory element.
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SREBP-1 and SREBP-2 (Sato, 2010). SREBPs activate the
genes encoding nearly every key enzyme in both the fatty acid
and sterol biosynthetic pathways (Horton et al., 2002). Transcrip-
tional regulation by mutant p53 may occur in many cases
through interactions with other sequence-specific transcription
factors binding to their cognate sites (Brosh and Rotter, 2009).
We hypothesized that mutant p53 might serve as a coactivator
with one or more of the SREBPs. The following experiments
support this hypothesis.
First, cotransiently expressed mutant p53 (p53-R273H) can
interact with the mature forms of all three family members,
SREBP-1a, SREBP-1c, and SREBP-2 (Figure 6A); endogenous
mutant p53 can be coimmunoprecipitated with endogenous
mature SREBP-2 in MDA-468 cells (Figure 6B) and MDA-231
cells (Figure S6A).
Second, in addition to the seven sterol biosynthesis genes
uncovered by our initial pathway analysis, we validated ten
additional SREBP-regulated sterol biosynthesis genes that are
regulated bymutant p53 inMDA-468 cells (Figure S6C), a subset
of which is also regulated in MDA-231 cells (Figure S6D). Of
note, DHCR24 was previously reported to be a transactivation
target of another tumor-derived mutant, p53-R175H (Bossi
et al., 2008). SREBP target genes that are not part of the meval-
onate pathway are also regulated by mutant p53 in MDA-468
cells (Figure S6E). Three such genes (FASN, ELOVL6, and
SCD) encode key enzymes within the fatty acid biosynthesis
pathway, suggesting that this pathway may also be upregulated
by mutant p53. Further, when a comprehensive list of SREBP
target genes was queried (Reed et al., 2008), there was amarked
enrichment of SREBP target genes in the set of genes that were
affected after mutant p53 depletion from breast cancer cells
(Figure S6B).
Third, mutant p53 is recruited to the promoter regions of genes
encoding sterol biosynthesis enzymes. Using quantitative chro-
matin immunoprecipitation (ChIP) analysis ofMDA-468 cells with
or without full levels of mutant p53, we identified significant
binding bymutant p53 in the vicinity of sterol regulatory elements
(SRE-1), the cognate binding sites for the SREBPs, in the
promoter regions of all seven genes tested (Figures 6C and
6D). This ChIP signal varied from 2- to 4-fold greater than the
signal at a negative region within the CDKN1A gene locus and
was consistently reduced upon depletion of p53 (Figure 6C).
ChIP analysis scanning regions upstream and downstream of
the transcriptional start site (TSS) of the gene encoding HMG-
CoA reductase (HMGCR) identified a region of peak binding by
mutant p53 150 bp upstream of the TSS (Figure 6D), which
corresponds to the known sterol regulatory element. The peak
signal, which was on the order of 3-fold greater than the negative
region, was again significantly reduced in cells with depleted p53
(Figure 6D).(E)MDA-468 cells were treatedwith siRNA targeting SREBP-2 andwere subjected
site in the HMGCR promoter (150 bp). Data are presented as mean ± SD of thre
knockdown.
(F) MDA-468.shp53 cells were treated with Fatostatin (20 mM) and subjected to
experiments. **p < 0.01.
(G) MDA-231.shp53 cells were grown in 3D cultures for 8 days and treated with D
images are shown. Scale bar, 200 mm.
See also Figure S6.Fourth, SREBPs are likely necessary for the full recruitment of
mutant p53 to these gene promoters. Depletion of SREBP-2
substantially decreased the recruitment of mutant p53 to the
HMG-CoA reductase gene promoter (Figure 6E), and depletion
of SREBP-1 slightly but significantly reduced the level of binding
to the same promoter (Figure S6).
Fifth, Fatostatin, a recently described inhibitor of SREBP acti-
vation (Kamisuki et al., 2009), significantly reduced the level of
mutant p53 binding to the HMG-CoA reductase gene promoter
(Figure 6F). Further, Fatostatin treatment had a dramatic effect
on the 3D morphology of MDA-231 cells (Figure 6G) and
MDA-468 cells (data not shown). Taken together, our results
strongly implicate a functional interaction with SREBPs as being
critical for mutant p53-mediated upregulation of the mevalonate
pathway genes.
TP53 Mutation Correlates with Elevated Expression
of Mevalonate Pathway Genes in Human Breast
Cancer Patients
To investigate whether the regulation of the mevalonate
pathway by mutant p53 is generalizable to human patients, we
examined five data sets consisting of a total of 812 human
breast cancer patient samples with expression data (728 had
known TP53 mutational status). After stratifying patients based
on the p53 mutational status of their tumors, we investigated
the expression level of 17 mevalonate pathway genes. Remark-
ably, 11 of these exhibited significantly higher expression
levels in mutant p53 breast tumors compared to those bearing
wild-type p53 across multiple data sets (Figures 7A and S7
and Table S1).
We also performed a reciprocal analysis on these same patient
data sets, stratifying tumors based on the expression of the me-
valonate pathway genes and examining the mutation rate of
TP53. Three main groups were observed from the hierarchical
clustering of the expression matrix from 17 sterol biosynthesis
genes on the 812 human breast cancer patient samples. Cluster
I has the lowest sterol biosynthesis gene expression pattern
and the lowest rate of TP53 mutations (14.1%). Cluster III
exhibits an intermediate expression level and an intermediate
rate of TP53 mutations (34.6%). Cluster II has the highest
expression pattern and exhibits the highest rate of TP53 muta-
tions (39.5%) (Figure 7B).
To test the biological significance of elevation of the mevalo-
nate pathway in mutant p53 tumors, we examined whether
upregulation of this pathway correlated with patient prognosis.
It is striking that cluster I, which has the lowest expression level
of the mevalonate pathway genes, is correlated with a more
favorable prognosis, whereas cluster III, which has an interme-
diate expression pattern, correlates with an intermediate
prognosis and cluster II, which has the highest expression ofto ChIP analysis as in (C) formutant p53 recruitment to the vicinity of the SRE-1
e independent experiments. *p < 0.05. See Figure S5C for extent of SREBP-2
ChIP analysis as in (E). Data are presented as mean ± SD of six independent
MSO, Fatostatin (2 or 20 mM). Drugs were added on day 1. Representative DIC
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Figure 7. Mutant p53 Is Correlated with Higher Expression of a Subset of Mevalonate Pathway Genes in Human Breast Cancer Patient
Data Sets
(A) Five human breast cancer patient data sets (see Supplemental Information for details) were analyzed to determine whether tumors bearing mutant p53
correlate with higher expression of sterol biosynthesis genes. Patients were stratified based on TP53 status (wild-type versus mutant), and expression levels for
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the mevalonate pathway genes, is associated with a significantly
poorer survival probability (Figure 7C). Therefore, not only was
elevation of the mevalonate pathway significantly correlated
with a higher rate of p53 mutations, but these breast cancer
patients also had a significantly decreased survival. We then
examined each sterol biosynthesis gene individually to investi-
gate which genes contribute the most to the prognostic value.
Elevated expression of nine mevalonate pathway genes corre-
lated with significantly poorer prognosis in these breast cancer
patients (Figure 7D).
Because breast cancer cells bearing mutant p53 appear to be
particularly sensitive to inhibition of the mevalonate pathway
in the 3D culture system, the fact that multiple members of this
pathway are upregulated in mutant p53 expressing human
tumors and correlate with a poor prognosis may have important
therapeutic implications.
DISCUSSION
Despite being one of the most well-studied tumor suppressors,
there is much evidence that, once mutated, p53 can actively
promote the progression of many cancers. With respect to
breast cancer, tumor-derived mutants of p53 have been impli-
cated in survival, chemoresistance, invasion, migration, and
metastasis (Brosh and Rotter, 2009). Because mammary tissue
architecture is invariably disrupted during breast carcinogen-
esis, we sought to delineate the phenotypic effects of mutant
p53 in breast cancer. We show that mutant p53 elevates
expression of many mevalonate pathway genes and that flux
through the mevalonate pathway is necessary and sufficient
for the phenotypic effects of mutant p53 on breast cancer cell
morphology in 3D culture.
The mevalonate pathway has been implicated in multiple
aspects of tumorigenesis, including proliferation, survival, inva-
sion, and metastasis (Clendening et al., 2010; Kidera et al.,
2010; Koyuturk et al., 2007). Competitive inhibitors of the rate-
limiting enzyme in the mevalonate pathway HMG-CoA reduc-
tase, collectively known as statins, have been reported to be
cancer protective for certain malignancies, including breast
cancer (Ahern et al., 2011; Blais et al., 2000; Cauley et al.,
2003). Yet, the cancer-protective effects of statins are not
without debate (Baigent et al., 2005; Browning and Martin,
2007). Statins have already been employed inmultiple preclinical
models of breast cancer (Kubatka et al., 2011; Shibata et al.,
2004). In line with this, we were also able to confirm a significantsterol biosynthesis genes were analyzed. Isopentenyl pyrophosphate isomerase (I
type p53 tumors (p < 0.05) across all five data sets. p value represents the resul
(B) Unsupervised hierarchical clustering with Euclidean distance and ward linkag
(728 of which have TP53mutational status).MVDwas not present in the DBCG dat
indicate the identity of the genes and columns indicate the identity of the patient
column. Cluster I exhibits the lowest expression of the mevalonate pathway gene
highest expression level of the mevalonate pathway genes.
(C) The Kaplan-Meier curves for the resulting clusters from the unsupervised hie
(D) Estimated hazard ratios (HRs; the relative risk for one unit increasing in the ge
death. Expression levels of following genes were positively associated with the ri
(HR = 1.23, q = 0.0069), HMGCS1 (HR = 1.21, q = 0.007), HMGCR (HR = 1.17, q
1.35, q < 0.001), LSS (HR = 1.16, q = 0.032), NSDHL (HR = 1.17, q = 0.032), and D
See also Figure S7.impact of Simvastatin treatment onMDA-231 breast cancer cells
in vivo.
Interestingly, at least one clinical study investigating the effect
of statins in breast cancer noted a subgroup-specific protective
effect: a significantly decreased incidence of hormone receptor-
negative (ER/PR) tumorswas documented in patients takings
statins, though no such effect was observed for hormone
receptor-positive tumors (Kumar et al., 2008). Preclinical models
employing either breast cancer cell lines or mouse models of
breast cancer also support a more dramatic role for statins in
ER/PR breast cancers (Campbell et al., 2006; Garwood
et al., 2010). Because the majority of breast tumors that bear
p53 mutations most commonly are also immunohistochemically
classified as ER/PR (Sørlie et al., 2001), it is tempting to
speculate that the antitumorigenic effects of statins are a
consequence of mutant p53’s upregulation of the mevalonate
pathway.
Gene expression profiling of breast cancers has identified
specific subtypes with important clinical, biologic, and thera-
peutic implications (Perou et al., 2000). Using these expression
signatures, most p53 mutations cluster in the basal-like
subgroup of breast cancers, which has the poorest prognosis
and is notoriously difficult to treat (Sørlie et al., 2001). Using
a combination of expression signatures and data from more
than 40,000 compounds screened in the NCI-60 cell lines, three
FDA-approved drugs were predicted to be most effective for
treating basal-like breast cancers, two of which, Simvastatin
and Lovastatin, are inhibitors of HMG-CoA reductase (Mori
et al., 2009). It will be exciting to examine whether stratifying
breast cancer patients based on their p53 mutational status
can resolve the apparent discrepancies within the rich body of
literature linking statins and cancer.
Although we have demonstrated that metabolic flux through
the mevalonate pathway is necessary to maintain the malignant
state, with a specific reliance on geranylgeranylation, we cannot
rule out the possibility that one or more other metabolites are
involved in the phenotypic effects that we observe in 3D culture.
If geranylgeranyl pyrophosphate is, in fact, the key metabolite, it
will be very interesting to delineate the geranylgeranylated
protein target(s) that mediate the oncogenic effects of themeval-
onate pathway in breast cancer cells in 3D culture.
In addition to the mevalonate pathway, a number of fatty acid
biosynthesis genes were also significantly affected by mutant
p53 depletion from breast cancer cells in 3D culture (Figures
3B and S6E). Intriguingly, this is the other major pathwayDI1) exhibited higher expression levels inmutant p53 tumors compared towild-
t of a one-sided t test. See Figure S7 and Table S1 for other genes.
e of expression matrix from the 17 sterol biosynthesis genes on 812 samples
a set, and its missing expression values were grayed out on the heatmap. Rows
s. The TP53 mutational status for each tumor is depicted directly above each
s, cluster III exhibits an intermediate expression level, and cluster II exhibits the
rarchical clustering in (B).
ne expression) with 95% confidence interval for risk of breast cancer-specific
sk of breast cancer specific death at false discovery rate (FDR) (q) 5%: ACAT2
= 0.032), IDI1 (HR = 1.26, q < 0.001), FDPS (HR = 1.17, q = 0.012), SQLE (HR =
HCR7 (HR = 1.26, q < 0.001). Blue indicates q < 0.05; gray indicates q > 0.05.
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controlled by the SREBP family of transcription factors (Horton
et al., 2002). Though much of our data points to a role for SREBP
proteins in the regulation of the mevalonate pathway by mutant
p53, a direct link is yet to be established. This regulation is likely
to occur through one or more of the SREBP proteins, but we
cannot rule out the possibility that another factor or factors
may also be involved. Mutant p53 may interact directly with
elements in the promoters of the sterol biosynthesis genes or
alternatively be recruited by a known mutant p53-interacting
partner such as NF-Y, SP1, Ets-1, or VDR, which have been
shown to recruit mutant p53 to their cognate binding sites (Brosh
and Rotter, 2009; Stambolsky et al., 2010).
Several scenarios have been proposed to explain why human
tumors select for mutations in p53. First, mutant p53 may simply
be selected for due to loss of wild-type p53 tumor-suppressive
activity. Second,mutant p53may acquire neomorphic (i.e., novel
gain-of-function) activities that promote tumor growth, many of
which have actually been shown to be diametrically opposed
to those performed by wild-type p53 (Peart and Prives, 2006;
Stambolsky et al., 2010). In line with this hypothesis are the find-
ings that Stearoyl-CoA desaturase (encoded bySCD) is a repres-
sion target of wild-type p53 (Mirza et al., 2003) and that wild-type
p53 can suppress a subset of SREBP target genes in a mouse
model of obesity (Yahagi et al., 2003). As the prosurvival roles
of wild-type p53 becomemore apparent (Kim et al., 2009), a third
scenario can be envisaged in which mutant p53 may retain and
exaggerate certain wild-type p53 functions while selectively
losing certain tumor-suppressivemechanisms such as the ability
to induce cell-cycle arrest and apoptosis. Regarding the latter
two hypotheses, it will be interesting for future studies to
examine whether wild-type p53 and/or its family members (p63
and p73) serve to repress sterol biosynthesis genes. Alterna-
tively, the maintenance of high levels of sterol biosynthesis
genes by mutant p53 may be a remnant of an unrecognized
wild-type p53 function.
In summary, our results demonstrate that mutant p53 can
disrupt mammary acinar morphology and that downregulation
of mutant p53 frommalignant cells is sufficient to phenotypically
revert these cells. Here, we propose one mechanism, the upre-
gulation of the mevalonate pathway, although one or more
additional pathways may play a role. Specifically, we demon-
strate that mutant p53 is recruited to the promoters of many
sterol biosynthesis genes, leading to their upregulation. We
hypothesize that tumors bearing p53 mutations evolve to
become highly reliant on metabolic flux through the mevalonate
pathway, making them particularly sensitive to inhibition of this
pathway. At a clinical level, inhibition of the mevalonate
pathway, either alone or in combination with other therapies,
may offer a much needed therapeutic option for tumors bearing
mutant p53.EXPERIMENTAL PROCEDURES
Three-Dimensional Culture
Three-dimensional culture was carried out as previously described (Debnath
et al., 2003). In brief, 8-well chamber slides were lined with growth factor-
reduced Matrigel, and cells were seeded in assay medium containing 2%
Matrigel.256 Cell 148, 244–258, January 20, 2012 ª2012 Elsevier Inc.Immunostaining and Microscopy
Cells were fixed using 2% formaldehyde. Confocal microscopy was conduct-
ed using an Olympus IX81 confocal microscope and analyzed using Fluoview
software.
Microarray and Data Analysis
MDA-468.shp53 cells cultured under 3D conditions were assayed for genome-
wide expression changes by Affymetrix GeneChip array, analyzed with
Ingenuity Pathway Analysis and Gene Ontology (GO) analysis.
Quantitative RT-PCR
As described in Barsotti and Prives (2009). Primer sequences are provided in
Table S2.
Drug Treatments
Cells in 3D culture were treated on day 1 or day 4 of the 3D protocol (as
described in the figure legends) and refed every 4 days with fresh drug.
Add-Back Experiments
On day 1, 3D culture cells cultured in the presence of doxycycline or Simvas-
tatin were supplemented with MVA/MVAP or GGPP and refed every 4 days.
Quantitative Chromatin Immunoprecipitation
As previously described in Beckerman et al. (2009). Primer sequences are
provided in Table S2.
Patient Data
Expression data for the sterol biosynthesis genes were extracted from indi-
vidual cohorts (FW-MDG, MicMa, Ull, DBCG, and Miller). Expression values
of the 17 sterol biosynthesis genes on 812 samples were clustered using hier-
archical clustering with Euclidean distance and ward linkage. The Kaplan-
Meier survival curves were plotted for the resulting groups, and the differences
in clinical indications among the clusters were tested by a logrank test.
ACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession number of the microarray
data reported in this paper is GSE31812.
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